H.C. Wainwright analyst Joseph Pantginis initiated coverage of ProKidney with a Buy rating and $12 price target. The company is pioneering an approach to postponing progressive kidney dysfunction, the analyst tells investors in a research note. The firm says ProKidney is a late clinical-stage biopharmaceutical company developing rilparencel, an investigational autologous cell therapy targeting patients with moderate to severe chronic kidney disease and type 2 diabetes. It believes rilparencel has the potential to redefine the therapeutic landscape of chronic kidney disease.
